StockNews.com assumed coverage on shares of Pro-Dex (NASDAQ:PDEX – Get Rating) in a report published on Tuesday. The firm issued a buy rating on the medical instruments supplier's stock.

Pro-Dex Stock Down 2.9 %

NASDAQ:PDEX opened at $16.89 on Tuesday. The company has a quick ratio of 1.39, a current ratio of 2.73 and a debt-to-equity ratio of 0.41. The stock's fifty day moving average is $16.98 and its two-hundred day moving average is $17.46. Pro-Dex has a 52 week low of $12.40 and a 52 week high of $26.50. The stock has a market capitalization of $60.47 million, a price-to-earnings ratio of 16.24 and a beta of 0.94.

Get Pro-Dex alerts:

Pro-Dex (NASDAQ:PDEX – Get Rating) last posted its quarterly earnings data on Thursday, November 3rd. The medical instruments supplier reported $0.29 earnings per share for the quarter. Pro-Dex had a return on equity of 16.75% and a net margin of 8.97%. The business had revenue of $11.09 million for the quarter.

Hedge Funds Weigh In On Pro-Dex

Several large investors have recently bought and sold shares of the business. Dimensional Fund Advisors LP boosted its stake in shares of Pro-Dex by 2.7% during the third quarter. Dimensional Fund Advisors LP now owns 58,126 shares of the medical instruments supplier's stock worth $1,030,000 after buying an additional 1,535 shares during the period. LSV Asset Management lifted its position in Pro-Dex by 13.9% in the first quarter. LSV Asset Management now owns 35,581 shares of the medical instruments supplier's stock valued at $588,000 after purchasing an additional 4,346 shares during the period. JPMorgan Chase & Co. lifted its position in Pro-Dex by 59.2% in the first quarter. JPMorgan Chase & Co. now owns 20,863 shares of the medical instruments supplier's stock valued at $345,000 after purchasing an additional 7,762 shares during the period. State Street Corp lifted its position in Pro-Dex by 5.8% in the first quarter. State Street Corp now owns 11,923 shares of the medical instruments supplier's stock valued at $197,000 after purchasing an additional 650 shares during the period. Finally, Renaissance Technologies LLC acquired a new stake in Pro-Dex in the second quarter valued at about $168,000. Hedge funds and other institutional investors own 13.49% of the company's stock.

About Pro-Dex

(Get Rating)

Pro-Dex, Inc engages in the design, development and manufacture of rotary drive surgical and dental instruments. The firm specializes in medical devices and services, industrial and scientific, dental and component, repairs and other. Its products include finished medical devices, micro air-motors, dental products, plastic injection molding and torque wrenches.

Featured Stories

• Get a free copy of the StockNews.com research report on Pro-Dex (PDEX)
• MarketBeat Week in Review – 1/23- 1/27
• Why Lucid Spiked Nearly 100% In One Day
• Ride These Railroad Stocks for Growth and Income
• ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
• KLA Corporation: Strength In A Troubled Semi-Market

Receive News & Ratings for Pro-Dex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pro-Dex and related companies with MarketBeat.com's FREE daily email newsletter.